Mariner LLC Sells 5,060 Shares of Moderna, Inc. (NASDAQ:MRNA)

Mariner LLC lowered its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 22.8% in the fourth quarter, HoldingsChannel reports. The firm owned 17,127 shares of the company’s stock after selling 5,060 shares during the period. Mariner LLC’s holdings in Moderna were worth $712,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. FMR LLC boosted its stake in shares of Moderna by 7.4% during the 4th quarter. FMR LLC now owns 18,664,634 shares of the company’s stock worth $776,075,000 after acquiring an additional 1,282,469 shares during the period. Geode Capital Management LLC increased its holdings in shares of Moderna by 2.4% in the fourth quarter. Geode Capital Management LLC now owns 7,241,354 shares of the company’s stock valued at $300,219,000 after purchasing an additional 171,774 shares during the last quarter. Invesco Ltd. increased its holdings in shares of Moderna by 24.3% in the fourth quarter. Invesco Ltd. now owns 5,006,462 shares of the company’s stock valued at $208,169,000 after purchasing an additional 979,858 shares during the last quarter. Norges Bank bought a new position in shares of Moderna in the fourth quarter valued at about $163,833,000. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Moderna by 9.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,344,203 shares of the company’s stock worth $97,472,000 after buying an additional 211,426 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Trading Up 1.3 %

MRNA stock opened at $27.82 on Wednesday. The firm has a 50-day moving average price of $29.91 and a 200-day moving average price of $38.08. Moderna, Inc. has a 12 month low of $23.15 and a 12 month high of $170.47. The stock has a market capitalization of $10.76 billion, a P/E ratio of -3.00 and a beta of 2.23.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on MRNA shares. Morgan Stanley lowered their price target on shares of Moderna from $39.00 to $32.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 9th. Berenberg Bank lifted their price target on Moderna from $33.00 to $42.00 and gave the stock a “hold” rating in a report on Thursday, January 16th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $40.00 price objective on shares of Moderna in a report on Tuesday, February 18th. Barclays downgraded Moderna from an “overweight” rating to an “equal weight” rating and dropped their target price for the stock from $111.00 to $45.00 in a report on Tuesday, February 18th. Finally, Leerink Partners decreased their price target on shares of Moderna from $31.00 to $27.00 and set an “underweight” rating on the stock in a research note on Thursday, January 16th. Four equities research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $58.70.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.